Updated software improves slicing for large-format 3D printing
The ExOne Company, the global leader in industrial sand and metal 3D printers using binder jetting technology, announced it has reached a commercial license agreement with Oak Ridge National Laboratory to 3D print parts in aluminum-infiltrated boron carbide.
Growing up in the heart of the American automobile industry near Detroit, Oak Ridge National Laboratory materials scientist Mike Kirka was no stranger to manufacturing.
The COHERENT particle physics experiment at the Department of Energy’s Oak Ridge National Laboratory has firmly established the existence of a new kind of neutrino interaction.
Algorithms developed at Oak Ridge National Laboratory can greatly enhance X-ray computed tomography images of 3D-printed metal parts, resulting in more accurate, faster scans.
In the quest for advanced vehicles with higher energy efficiency and ultra-low emissions, ORNL researchers are accelerating a research engine that gives scientists and engineers an unprecedented view inside the atomic-level workings of combustion engines in real time.
As ORNL’s fuel properties technical lead for the U.S. Department of Energy’s Co-Optimization of Fuel and Engines, or Co-Optima, initiative, Jim Szybist has been on a quest for the past few years to identify the most significant indicators for predicting how a fuel will perform in engines designed for light-duty vehicles such as passenger cars and pickup trucks.
Six ORNL scientists have been elected as fellows to the American Association for the Advancement of Science, or AAAS.
The University of Texas at San Antonio (UTSA) has formally launched the Cybersecurity Manufacturing Innovation Institute (CyManII), a $111 million public-private partnership.
The annual Director's Awards recognized four individuals and teams including awards for leadership in quantum simulation development and application on high-performance computing platforms, and revolutionary advancements in the area of microbial
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.